Wednesday, April 24, 2024 4/24/2024

Linking Insulin Signaling to Antimicrobial Peptide Production and the Kidney's Antibacterial Defenses

Award Number: R01DK114035
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

ABSTRACT Diabetes mellitus is a systemic disorder that increases infection susceptibility. The most common site of infection is the urinary tract. Urinary tract infection (UTI) is more common, more severe, and has worse outcomes in people with diabetes. To date, the mechanisms that predispose people with diabetes to UTI have not been elucidated. This project will evaluate how insulin regulates innate immune mechanisms in the kidney’s intercalated cells. Surmounting evidence from our research group and others suggests that intercalated cells (IC) play a critical role in antibacterial defenses against uropathogenic E. coli (UPEC). Our research shows that insulin resistance and Type 2 diabetes mellitus increases UTI risk. When the insulin receptor is selectively deleted in murine ICs, UPEC susceptibility significantly increases in vivo. Also, we have demonstrated that insulin induces antimicrobial peptide (AMP) expression in primary human renal epithelial cells via the phosphatidylinositide 3-kinase (PI3K/AKT) signaling pathway. Specifically, our data show that insulin induces Ribonuclease 7 (RNase 7) production, the most potent AMP in the human urinary tract, to shield the urothelium from UPEC. Together, these data provide strong support for our hypothesis that insulin signaling plays an essential role in innate IC defenses by regulating PI3K/AKT activity and downstream AMP production. Building on these previous studies, we propose a comprehensive analysis of insulin’s ability to regulate IC defense mechanisms. Aim 1 will evaluate how insulin resistance and Type 2 diabetes mellitus affects IC antibacterial defenses. Aim 2 will identify how IC insulin receptor deletion impacts AMP transcription and whether targeted PI3K/AKT activation induces AMP expression. Aim 3 will use a novel transgenic humanized mouse model to assess how insulin resistance and insulin therapy impacts the production of RNase 7 and its antimicrobial activity in vivo. The long-term objective of this project is to improve the care of diabetic patients with UTI by identifying novel therapeutic options. By evaluating the role of insulin signaling in host defense, completion of these Aims can have profound influence on the health of people with diabetes as they may develop insulin-signaling targets, like PI3K/AKT and RNase 7, as new therapeutics that prevent UTI, extending UTI treatment options beyond the scope of antibiotics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	3/23/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $345,499 )
2021	2021	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	2/15/2021	NON-COMPETING CONTINUATION	$345,499
														Subtotal = $345,499

Issue Date FY: 2020 ( Subtotal = $342,000 )
2020	2020	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	2/24/2020	NON-COMPETING CONTINUATION	$342,000
														Subtotal = $342,000

Issue Date FY: 2019 ( Subtotal = $342,000 )
2019	2019	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	3/1/2019	NON-COMPETING CONTINUATION	$342,000
														Subtotal = $342,000

Issue Date FY: 2018 ( Subtotal = $342,000 )
2018	2018	RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	700 CHILDRENS DR	COLUMBUS	OH	43205	FRANKLIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	4/2/2018	NEW	$342,000
														Subtotal = $342,000

Grand Total All Awards = $1,371,499

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Linking Insulin Signaling to Antimicrobial Peptide Production and the Kidney's Antibacterial Defenses

Award Number: R01DK114035

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer